TherapeuticsMD
TXMD
142 hedge funds and large institutions have $190M invested in TherapeuticsMD in 2020 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 40 increasing their positions, 53 reducing their positions, and 33 closing their positions.
19% more call options, than puts
Call options by funds: $796K | Put options by funds: $669K
0.07% less ownership
Funds ownership: 1.42% → 1.35% (-0.07%)
15% less funds holding
Funds holding: 168 → 142 (-26)
25% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 53
59% less capital invested
Capital invested by funds: $467M → $190M (-$277M)
67% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
GMT Capital
Atlanta,
Georgia
|
+$10.2M |
| 2 |
SMH
Sanders Morris Harris
Houston,
Texas
|
+$6.71M |
| 3 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$5.95M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$2.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$15.5M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$5.73M |
| 3 |
DM
Deerfield Management
New York
|
-$5.45M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$3.72M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$2.78M |
TXMD Hedge Fund Activity: Q1 2020 in Review
142 of the 4,546 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q1 2020, worth a combined $190M — down 59% from $467M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of TXMD and 11 opened new positions — a net loss of 22 holders — while 53 trimmed existing stakes and 40 added.
The largest buyer was GMT Capital, opening a new position worth an estimated $10.2M. The largest seller was Frontier Capital Management, exiting entirely with an estimated $15.5M sold.
- 142 institutional investors held TherapeuticsMD (TXMD) as of Q1 2020, down from 168 in Q4 2019.
- Funds reported $190M of TherapeuticsMD stock for Q1 2020, down 59% quarter-over-quarter.
- 11 funds opened new TherapeuticsMD positions in Q1 2020 and 33 closed out, a net change of -22 holders.
- The largest TherapeuticsMD buyer in Q1 2020 was GMT Capital, an estimated $10.2M added.
- The largest TherapeuticsMD seller in Q1 2020 was Frontier Capital Management, an estimated $15.5M sold.
Based on aggregated 13F filings for Q1 2020.